Page last updated: 2024-11-05

ticlopidine and Hyperuricemia

ticlopidine has been researched along with Hyperuricemia in 1 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.

Research Excerpts

ExcerptRelevanceReference
"Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses."4.02Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia. ( Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Lee, S1
Wadowski, PP1
Hoberstorfer, T1
Weikert, C1
Pultar, J1
Kopp, CW1
Panzer, S1
Gremmel, T1

Other Studies

1 other study available for ticlopidine and Hyperuricemia

ArticleYear
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:1

    Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochr

2021